Vertex Pharmaceuticals Could Surprise with JOURNAVX and CASGEVY
The product business is expected to be further diversified this year
Sales of $11 billion - double-digit growth rates have been recorded for 10 consecutive years
Reading Time: 2 minutes
Vertex Pharmaceuticals (VRTX) is a market leader in the treatment of cystic fibrosis (CF) and has so far been heavily reliant on its core product TRIKAFTA, which accounts for 93% of its revenue mix. However, revenue diversification is expected to gain further momentum with JOURNAVX and CASGEVY now. I am convinced that the big-picture breakout will happen soon. TRIKAFTA grew nearly 17% in the fourth quarter. ALYFTREK could potentially replace TRIKAFTA as the only CFTR modulator of the next generation taken once instead of twice daily, thus expanding...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
